Quince Therapeutics (NASDAQ:QNCX) Raised to “Strong-Buy” at Lifesci Capital

Quince Therapeutics (NASDAQ:QNCX) was upgraded by stock analysts at Lifesci Capital to a “strong-buy” rating in a research note issued on Monday,Zacks.com reports.

Other equities research analysts also recently issued reports about the company. Weiss Ratings downgraded Quince Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. Wall Street Zen upgraded shares of Quince Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, May 17th. Zacks Research raised shares of Quince Therapeutics to a “hold” rating in a report on Wednesday, June 24th. Cantor Fitzgerald initiated coverage on shares of Quince Therapeutics in a research report on Tuesday, June 23rd. They set an “overweight” rating and a $80.00 target price for the company. Finally, Leerink Partners assumed coverage on shares of Quince Therapeutics in a report on Wednesday, June 24th. They set an “outperform” rating and a $80.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $690.00.

Quince Therapeutics Trading Down 2.4%

Shares of QNCX opened at $0.92 on Monday. The firm has a fifty day simple moving average of $1.11 and a two-hundred day simple moving average of $9.47. The firm has a market cap of $15.01 million, a PE ratio of -0.09 and a beta of 1.40. Quince Therapeutics has a 1-year low of $0.79 and a 1-year high of $45.50.

Quince Therapeutics (NASDAQ:QNCX) last released its quarterly earnings results on Monday, May 11th. The company reported ($11.80) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($26.00) by $14.20. As a group, research analysts forecast that Quince Therapeutics will post -0.43 EPS for the current fiscal year.

Hedge Funds Weigh In On Quince Therapeutics

A number of hedge funds have recently made changes to their positions in QNCX. Geode Capital Management LLC raised its stake in Quince Therapeutics by 19.8% during the 4th quarter. Geode Capital Management LLC now owns 523,899 shares of the company’s stock valued at $1,756,000 after purchasing an additional 86,614 shares during the period. Jane Street Group LLC boosted its stake in Quince Therapeutics by 1,382.0% in the 4th quarter. Jane Street Group LLC now owns 521,072 shares of the company’s stock worth $1,746,000 after purchasing an additional 485,912 shares during the period. Marshall Wace LLP grew its holdings in Quince Therapeutics by 143.7% during the 4th quarter. Marshall Wace LLP now owns 511,858 shares of the company’s stock valued at $1,715,000 after buying an additional 301,813 shares in the last quarter. ADAR1 Capital Management LLC raised its position in shares of Quince Therapeutics by 442.1% during the third quarter. ADAR1 Capital Management LLC now owns 775,034 shares of the company’s stock valued at $1,263,000 after buying an additional 632,076 shares during the last quarter. Finally, Cerity Partners LLC bought a new stake in shares of Quince Therapeutics during the fourth quarter valued at approximately $636,000. Institutional investors own 30.75% of the company’s stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.